llms.txt written: 3015 bytes

European Manufacturers: Using the Caribbean Corridor for U.S. Market Entry

By April 5, 2026Blog

QUICK ANSWER

European manufacturers in Germany, Italy, France, and Eastern Europe use the Caribbean Corridor to access the U.S. market through Dominican Republic free zones — combining CAFTA-DR duty-free U.S. entry, zero income tax under Law 8-90, and 3–4 day sea transit to Miami, at manufacturing costs significantly below European domestic levels.

The European Market Entry Problem

European manufacturers face substantial barriers to direct U.S. market entry: MFN tariffs on most European exports to the U.S., high domestic manufacturing costs that compress U.S. market margins, the complexity and capital requirement of establishing U.S. operations, and the absence of a comprehensive EU-U.S. free trade agreement providing duty-free access for manufactured goods. The Caribbean Corridor addresses each barrier by routing manufacturing through a CAFTA-DR qualifying jurisdiction.

Why the DR Over Other Options

European manufacturers have historically looked at Mexico (USMCA) as the primary Americas manufacturing option. The Dominican Republic offers comparable labor costs with a structurally superior free zone tax package: full income tax exemption under Law 8-90 versus Mexico’s deferral-based IMMEX program. The DR also presents lower operational complexity and security risk for European management teams with limited Americas experience.

Sectors With High European Activity

German and Italian manufacturers in medical devices, precision components, and specialty chemicals have found the DR’s combination of CAFTA-DR access and established medical device manufacturing infrastructure particularly compelling. Eastern European manufacturers in light electronics, plastics, and packaging have used DR free zones as a U.S. market entry vehicle where European labor costs have become uncompetitive versus Asian alternatives.

How EGS Structures European Corridor Mandates

EGS coordinates European corridor mandates across three dimensions: structuring the DR manufacturing entity and CNZFE license, establishing the cross-border supply chain from the European origin to DR production, and developing U.S. distribution infrastructure. For German or EU-based companies with CE-certified products targeting U.S. FDA-regulated markets, EGS coordinates the regulatory alignment between European and U.S. compliance frameworks. Submit an inquiry to assess your mandate.

Leave a Reply

Share